[ET Net News Agency, 15 October 2019] UBS Global Research lifted slightly its target
price for Luye Pharma Group (02186) to HK$7.8 from HK$7.66 and upgraded its rating to
"buy" from "neutral" on low valuation.
The research house fine-tuned its 2019-21 EPS (diluted) forecasts by 4-7%
With differentiated labels from Nab-paclitaxel and room for normal paclitaxel and
docetaxel (P&D) replacement, UBS thinks Lipusu (LPS) revenue growth could remain steady in
2019-20 and stay around Rmb2.3bn by 2024, despite competition from Nab-paclitaxel.
UBS expects the launch of new drugs in 2020-22 to offset a potential LPS decline over
the longer run. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02186 LUYE PHARMA
Nominal 
2.720 +0.030 (+1.115%) Research Report
15/10/2019 11:25
{I-bank focus}UBS upgrades Luye Pharma (02186) to HK$7.8
| Remark: | Real time quote last updated: 25/04/2024 12:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |